Prolonged blood circulation outperforms active targeting for nanocarriers-mediated enhanced hepatocellular carcinoma therapy in vivo

Huang, Cong; Ye, Peng-Ju; Long, Jinrong; Xu, Chenghu; Liu, Ying; X., Ling,; Lv, Shaoyang; He, Dongxiu; Wei, Hua; Yu, Cui‐Yun

doi:10.1016/j.jconrel.2022.05.024

Cited by 18 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zetasizer Nano ZS (malvern) was used to determine the average particle size and ζ potential of TPP-Pt- acetal -CA NPs. The serum stability of TPP-Pt- acetal -CA NPs was assessed by monitoring time-dependent size changes by DLS . TPP-Pt- acetal -CA NPs were incubated with PBS in the presence of 10% fetal bovine serum (FBS) for 48 h at 37 °C.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance  

et al. 2023

Self Cite

View full text Add to dashboard Cite

Scalable production of a clinically translatable formulation with enhanced therapeutic efficacy against cisplatin-resistant tumors without the use of any clinically unapproved reagents and additional manipulation remains a challenge. For this purpose, we report herein the construction of TPP-Pt-acetal-CA based on all commercially available, clinically approved reagents consisting of a cinnamaldehyde (CA) unit for reactive oxygen species generation, a mitochondrially targeted triphenylphosphonium (TPP)-modified Pt(IV) moiety for mitochondrial dysfunction, and an intracellular acidic pH-cleavable acetal link between these two moieties. The resulting self-assembled, stabilized TPP-Pt-acetal-CA nanoparticles mediated an IC 50 value approximately 6-fold lower than that of cisplatin in A549/DDP cells and a tumor weight reduction 3.6-fold greater than that of cisplatin in A549/DDP tumor-bearing BALB/c mice with insignificant systematic toxicity due to the synergistic mitochondrial dysfunction and markedly amplified oxidative stress. Therefore, this study presents the first example of a clinically translatable Pt(IV) prodrug with enhanced efficiency for synergistically reversing drug resistance.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The serum stability of TPP-Pt-acetal-CA NPs was assessed by monitoring timedependent size changes by DLS. 48 TPP-Pt-acetal-CA NPs were incubated with PBS in the presence of 10% fetal bovine serum (FBS) for 48 h at 37 °C. DLS measurements of TPP-Pt-acetal-CA NPs were conducted every 12 h.…”

Section: ■ Conclusionmentioning

confidence: 99%

A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance  

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Notably, the TPSD&D micelles exhibited an average diameter of approximately 147 nm and a PDI of 0.267. Research has confirmed that the ideal particle size for nanocarriers to achieve prolonged circulation in the blood and increased retention in tumor tissues is within the range of 50–200 nm. − As such, the prepared micelles possess the capability of extended in vivo circulation and impressive penetration into tumor tissues.…”

Section: Resultsmentioning

confidence: 99%

Enzyme and Reduction Dual-Responsive Peptide Micelles as Nanocarriers for Smart Drug Delivery

Chen,

Song,

Yang

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Chemotherapy remains the primary treatment for cancer; however, conventional chemotherapeutic drugs have several shortcomings, including poor solubility, lack of targeting, low bioavailability, and high toxicity to healthy tissues. In order to overcome these limitations, drug delivery systems (DDS) have emerged as a promising alternative. In this study, we synthesized TPGS3350-PVGLIG-SS-DOX polymeric micelles that incorporate both extracellular MMP2/9 enzyme response and intracellular reduction response at a nanoscale level. The micelles remained stable throughout the blood circulation and only aggregated at the tumor sites, thanks to the enhanced permeability and retention (EPR) effect. Moreover, the tumor tissue showed a high expression of MMP2/9 enzymes, which resulted in the cleavage of the PVGLIG peptide sequence, ultimately leading to an improved phagocytosis efficiency. Under the action of high intracellular GSH concentration, the disulfide bond was broken and DOX was released to induce tumor cell death. The TPSD&D micelles exhibited good tumor inhibitory activity in vivo and significantly reduced toxic side effects on normal tissues. Our work provides a simple method to assemble tumor-targeted prodrug micelles to improve cancer therapy, which holds potential for clinical applications in antitumor therapy.

show abstract

“…Chemotherapeutics usually exhibit low water solubility, high side effects, low bioavailability, rapid metabolism, and quick excretion in vivo. 1,2 To develop effective anticancer drugs with fewer side effects and prolong drug action, scientists have developed many different nanocarriers or nanotechnologies to prolong systemic drug circulation [3][4][5][6] and deliver drugs directly to lesions. [7][8][9][10][11] Thus, drug-based nanomedicines have become a hotspot in the drug delivery field.…”

Section: Introductionmentioning

confidence: 99%

A glutathione-responsive PEGylated nanogel with doxorubicin-conjugation for cancer therapy

Li,

Wang,

Duan

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Prolonged blood circulation outperforms active targeting for nanocarriers-mediated enhanced hepatocellular carcinoma therapy in vivo

Cited by 18 publications

References 36 publications

A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance

A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance

Enzyme and Reduction Dual-Responsive Peptide Micelles as Nanocarriers for Smart Drug Delivery

A glutathione-responsive PEGylated nanogel with doxorubicin-conjugation for cancer therapy

Contact Info

Product

Resources

About